APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR T-Cell-Based Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CAR T-Cell-Based Drug Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchCAR T-Cell-Based Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR T-Cell-Based Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CAR T-Cell-Based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR T-Cell-Based Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR T-Cell-Based Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global CAR T-Cell-Based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CAR T-Cell-Based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CAR T-Cell-Based Drug market include J & J, Novartis, Gilead Sciences, Bristol-Myers Squibb, Sorrento Therapeutics, Mustang Bio, JW Therapeutics, FOSUNKite and Celyad, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CAR T-Cell-Based Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CAR T-Cell-Based Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CAR T-Cell-Based Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CAR T-Cell-Based Drug market.

CAR T-Cell-Based Drug Segment by Company

J & J

Novartis

Gilead Sciences

Bristol-Myers Squibb

Sorrento Therapeutics

Mustang Bio

JW Therapeutics

FOSUNKite

Celyad

Cellectis

CARsgen Therapeutics

Bluebird Bio

Autolus Therapeutics

Allogene Therapeutics

CAR T-Cell-Based Drug Segment by Type

CD19-targeted

BCMA-targeted

CAR T-Cell-Based Drug Segment by Application

Lymphoma

Multiple Myeloma

CAR T-Cell-Based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CAR T-Cell-Based Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CAR T-Cell-Based Drug key companies, revenue, market share, and recent developments.

3. To split the CAR T-Cell-Based Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CAR T-Cell-Based Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CAR T-Cell-Based Drug significant trends, drivers, influence factors in global and regions.

6. To analyze CAR T-Cell-Based Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell-Based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell-Based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell-Based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR T-Cell-Based Drug industry.

Chapter 3: Detailed analysis of CAR T-Cell-Based Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CAR T-Cell-Based Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CAR T-Cell-Based Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CAR T-Cell-Based Drug Industry Trends Table 2. CAR T-Cell-Based Drug Industry Drivers Table 3. CAR T-Cell-Based Drug Industry Opportunities and Challenges Table 4. CAR T-Cell-Based Drug Industry Restraints Table 5. Global CAR T-Cell-Based Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CAR T-Cell-Based Drug Revenue Share by Company (2021-2026) Table 7. Global CAR T-Cell-Based Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CAR T-Cell-Based Drug Key Company Manufacturing Base & Headquarters Table 9. Global CAR T-Cell-Based Drug Company, Product Type & Application Table 10. Global CAR T-Cell-Based Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CAR T-Cell-Based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CD19-targeted Table 15. Significant Companies of BCMA-targeted Table 16. Global CAR T-Cell-Based Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CAR T-Cell-Based Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CAR T-Cell-Based Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CAR T-Cell-Based Drug Sales Value Share by Type (2021-2026) Table 20. Global CAR T-Cell-Based Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Lymphoma Table 22. Significant Companies of Multiple Myeloma Table 23. Global CAR T-Cell-Based Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global CAR T-Cell-Based Drug Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global CAR T-Cell-Based Drug Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global CAR T-Cell-Based Drug Sales Value Share by Application (2021-2026) Table 27. Global CAR T-Cell-Based Drug Sales Value Share by Application (2027-2032) Table 28. Global CAR T-Cell-Based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global CAR T-Cell-Based Drug Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global CAR T-Cell-Based Drug Sales Value Share by Region (2021-2026) Table 31. Global CAR T-Cell-Based Drug Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global CAR T-Cell-Based Drug Sales Value Share by Region (2027-2032) Table 33. Global CAR T-Cell-Based Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global CAR T-Cell-Based Drug Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global CAR T-Cell-Based Drug Sales Value Market Share by Country (2021-2026) Table 36. Global CAR T-Cell-Based Drug Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global CAR T-Cell-Based Drug Sales Value Market Share by Country (2027-2032) Table 38. J & J Company Information Table 39. J & J Business Overview Table 40. J & J CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. J & J CAR T-Cell-Based Drug Product Portfolio Table 42. J & J Recent Development Table 43. Novartis Company Information Table 44. Novartis Business Overview Table 45. Novartis CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Novartis CAR T-Cell-Based Drug Product Portfolio Table 47. Novartis Recent Development Table 48. Gilead Sciences Company Information Table 49. Gilead Sciences Business Overview Table 50. Gilead Sciences CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Gilead Sciences CAR T-Cell-Based Drug Product Portfolio Table 52. Gilead Sciences Recent Development Table 53. Bristol-Myers Squibb Company Information Table 54. Bristol-Myers Squibb Business Overview Table 55. Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio Table 57. Bristol-Myers Squibb Recent Development Table 58. Sorrento Therapeutics Company Information Table 59. Sorrento Therapeutics Business Overview Table 60. Sorrento Therapeutics CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 62. Sorrento Therapeutics Recent Development Table 63. Mustang Bio Company Information Table 64. Mustang Bio Business Overview Table 65. Mustang Bio CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Mustang Bio CAR T-Cell-Based Drug Product Portfolio Table 67. Mustang Bio Recent Development Table 68. JW Therapeutics Company Information Table 69. JW Therapeutics Business Overview Table 70. JW Therapeutics CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. JW Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 72. JW Therapeutics Recent Development Table 73. FOSUNKite Company Information Table 74. FOSUNKite Business Overview Table 75. FOSUNKite CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. FOSUNKite CAR T-Cell-Based Drug Product Portfolio Table 77. FOSUNKite Recent Development Table 78. Celyad Company Information Table 79. Celyad Business Overview Table 80. Celyad CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Celyad CAR T-Cell-Based Drug Product Portfolio Table 82. Celyad Recent Development Table 83. Cellectis Company Information Table 84. Cellectis Business Overview Table 85. Cellectis CAR T-Cell-Based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Cellectis CAR T-Cell-Based Drug Product Portfolio Table 87. Cellectis Recent Development Table 88. CARsgen Therapeutics Company Information Table 89. CARsgen Therapeutics Business Overview Table 90. CARsgen Therapeutics CAR T-Cell-Based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 92. CARsgen Therapeutics Recent Development Table 93. Bluebird Bio Company Information Table 94. Bluebird Bio Business Overview Table 95. Bluebird Bio CAR T-Cell-Based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Bluebird Bio CAR T-Cell-Based Drug Product Portfolio Table 97. Bluebird Bio Recent Development Table 98. Autolus Therapeutics Company Information Table 99. Autolus Therapeutics Business Overview Table 100. Autolus Therapeutics CAR T-Cell-Based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 102. Autolus Therapeutics Recent Development Table 103. Allogene Therapeutics Company Information Table 104. Allogene Therapeutics Business Overview Table 105. Allogene Therapeutics CAR T-Cell-Based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 107. Allogene Therapeutics Recent Development Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. CAR T-Cell-Based Drug Product Image Figure 2. Global CAR T-Cell-Based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global CAR T-Cell-Based Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CD19-targeted Image Figure 8. BCMA-targeted Image Figure 9. Global CAR T-Cell-Based Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CAR T-Cell-Based Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CAR T-Cell-Based Drug Sales Value Share by Type (2021-2032) Figure 12. Lymphoma Image Figure 13. Multiple Myeloma Image Figure 14. Global CAR T-Cell-Based Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global CAR T-Cell-Based Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global CAR T-Cell-Based Drug Sales Value Share by Application (2021-2032) Figure 17. Global CAR T-Cell-Based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global CAR T-Cell-Based Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America CAR T-Cell-Based Drug Sales Value (2021-2032) & (US$ Million) Figure 20. North America CAR T-Cell-Based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe CAR T-Cell-Based Drug Sales Value (2021-2032) & (US$ Million) Figure 22. Europe CAR T-Cell-Based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific CAR T-Cell-Based Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific CAR T-Cell-Based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America CAR T-Cell-Based Drug Sales Value (2021-2032) & (US$ Million) Figure 26. South America CAR T-Cell-Based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa CAR T-Cell-Based Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa CAR T-Cell-Based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • CD19-targeted
  • BCMA-targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • J & J
  • Novartis
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Sorrento Therapeutics
  • Mustang Bio
  • JW Therapeutics
  • FOSUNKite
  • Celyad
  • Cellectis
  • CARsgen Therapeutics
  • Bluebird Bio
  • Autolus Therapeutics
  • Allogene Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CAR T-Cell-Based Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CAR T-Cell-Based Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CAR T-Cell-Based Drug Market Dynamics
  1. 2.1 CAR T-Cell-Based Drug Industry Trends
  2. 2.2 CAR T-Cell-Based Drug Industry Drivers
  3. 2.3 CAR T-Cell-Based Drug Industry Opportunities and Challenges
  4. 2.4 CAR T-Cell-Based Drug Industry Restraints
3 CAR T-Cell-Based Drug Market by Company
  1. 3.1 Global CAR T-Cell-Based Drug Company Revenue Ranking in 2025
  2. 3.2 Global CAR T-Cell-Based Drug Revenue by Company (2021-2026)
  3. 3.3 Global CAR T-Cell-Based Drug Company Ranking (2024-2026)
  4. 3.4 Global CAR T-Cell-Based Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global CAR T-Cell-Based Drug Company Product Type and Application
  6. 3.6 Global CAR T-Cell-Based Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CAR T-Cell-Based Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CAR T-Cell-Based Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CAR T-Cell-Based Drug Market by Type
  1. 4.1 CAR T-Cell-Based Drug Type Introduction
  2. 4.1.1 CD19-targeted
  3. 4.1.2 BCMA-targeted
  4. 4.2 Global CAR T-Cell-Based Drug Sales Value by Type
  5. 4.2.1 Global CAR T-Cell-Based Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CAR T-Cell-Based Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global CAR T-Cell-Based Drug Sales Value Share by Type (2021-2032)
5 CAR T-Cell-Based Drug Market by Application
  1. 5.1 CAR T-Cell-Based Drug Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Multiple Myeloma
  4. 5.2 Global CAR T-Cell-Based Drug Sales Value by Application
  5. 5.2.1 Global CAR T-Cell-Based Drug Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global CAR T-Cell-Based Drug Sales Value by Application (2021-2032)
  7. 5.2.3 Global CAR T-Cell-Based Drug Sales Value Share by Application (2021-2032)
6 CAR T-Cell-Based Drug Regional Value Analysis
  1. 6.1 Global CAR T-Cell-Based Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CAR T-Cell-Based Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global CAR T-Cell-Based Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global CAR T-Cell-Based Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CAR T-Cell-Based Drug Sales Value (2021-2032)
  7. 6.3.2 North America CAR T-Cell-Based Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CAR T-Cell-Based Drug Sales Value (2021-2032)
  10. 6.4.2 Europe CAR T-Cell-Based Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CAR T-Cell-Based Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CAR T-Cell-Based Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CAR T-Cell-Based Drug Sales Value (2021-2032)
  16. 6.6.2 South America CAR T-Cell-Based Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CAR T-Cell-Based Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CAR T-Cell-Based Drug Sales Value Share by Country, 2025 VS 2032
7 CAR T-Cell-Based Drug Country-level Value Analysis
  1. 7.1 Global CAR T-Cell-Based Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CAR T-Cell-Based Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global CAR T-Cell-Based Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global CAR T-Cell-Based Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CAR T-Cell-Based Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CAR T-Cell-Based Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CAR T-Cell-Based Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 J & J
  2. 8.1.1 J & J Company Information
  3. 8.1.2 J & J Business Overview
  4. 8.1.3 J & J CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 J & J CAR T-Cell-Based Drug Product Portfolio
  6. 8.1.5 J & J Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis CAR T-Cell-Based Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences CAR T-Cell-Based Drug Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Sorrento Therapeutics
  26. 8.5.1 Sorrento Therapeutics Company Information
  27. 8.5.2 Sorrento Therapeutics Business Overview
  28. 8.5.3 Sorrento Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio
  30. 8.5.5 Sorrento Therapeutics Recent Developments
  31. 8.6 Mustang Bio
  32. 8.6.1 Mustang Bio Company Information
  33. 8.6.2 Mustang Bio Business Overview
  34. 8.6.3 Mustang Bio CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mustang Bio CAR T-Cell-Based Drug Product Portfolio
  36. 8.6.5 Mustang Bio Recent Developments
  37. 8.7 JW Therapeutics
  38. 8.7.1 JW Therapeutics Company Information
  39. 8.7.2 JW Therapeutics Business Overview
  40. 8.7.3 JW Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 JW Therapeutics CAR T-Cell-Based Drug Product Portfolio
  42. 8.7.5 JW Therapeutics Recent Developments
  43. 8.8 FOSUNKite
  44. 8.8.1 FOSUNKite Company Information
  45. 8.8.2 FOSUNKite Business Overview
  46. 8.8.3 FOSUNKite CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 FOSUNKite CAR T-Cell-Based Drug Product Portfolio
  48. 8.8.5 FOSUNKite Recent Developments
  49. 8.9 Celyad
  50. 8.9.1 Celyad Company Information
  51. 8.9.2 Celyad Business Overview
  52. 8.9.3 Celyad CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Celyad CAR T-Cell-Based Drug Product Portfolio
  54. 8.9.5 Celyad Recent Developments
  55. 8.10 Cellectis
  56. 8.10.1 Cellectis Company Information
  57. 8.10.2 Cellectis Business Overview
  58. 8.10.3 Cellectis CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Cellectis CAR T-Cell-Based Drug Product Portfolio
  60. 8.10.5 Cellectis Recent Developments
  61. 8.11 CARsgen Therapeutics
  62. 8.11.1 CARsgen Therapeutics Company Information
  63. 8.11.2 CARsgen Therapeutics Business Overview
  64. 8.11.3 CARsgen Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio
  66. 8.11.5 CARsgen Therapeutics Recent Developments
  67. 8.12 Bluebird Bio
  68. 8.12.1 Bluebird Bio Company Information
  69. 8.12.2 Bluebird Bio Business Overview
  70. 8.12.3 Bluebird Bio CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bluebird Bio CAR T-Cell-Based Drug Product Portfolio
  72. 8.12.5 Bluebird Bio Recent Developments
  73. 8.13 Autolus Therapeutics
  74. 8.13.1 Autolus Therapeutics Company Information
  75. 8.13.2 Autolus Therapeutics Business Overview
  76. 8.13.3 Autolus Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio
  78. 8.13.5 Autolus Therapeutics Recent Developments
  79. 8.14 Allogene Therapeutics
  80. 8.14.1 Allogene Therapeutics Company Information
  81. 8.14.2 Allogene Therapeutics Business Overview
  82. 8.14.3 Allogene Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio
  84. 8.14.5 Allogene Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst